132 related articles for article (PubMed ID: 26466937)
1. Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.
Inoue D; Muraoka R; Okazaki R; Nishizawa Y; Sugimoto T
Calcif Tissue Int; 2016 Feb; 98(2):114-22. PubMed ID: 26466937
[TBL] [Abstract][Full Text] [Related]
2. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
Mawatari T; Muraoka R; Iwamoto Y
Osteoporos Int; 2017 Apr; 28(4):1279-1286. PubMed ID: 27900428
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
[TBL] [Abstract][Full Text] [Related]
5. Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials.
Shigematsu T; Muraoka R; Sugimoto T; Nishizawa Y
BMC Nephrol; 2017 Feb; 18(1):66. PubMed ID: 28201994
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
Sugimoto T; Inoue D; Maehara M; Oikawa I; Shigematsu T; Nishizawa Y
J Bone Miner Metab; 2019 Jul; 37(4):730-740. PubMed ID: 30523414
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis.
Okazaki R; Muraoka R; Maehara M; Inoue D
J Bone Miner Metab; 2019 Jan; 37(1):185-197. PubMed ID: 29737412
[TBL] [Abstract][Full Text] [Related]
8. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
[TBL] [Abstract][Full Text] [Related]
9. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
[TBL] [Abstract][Full Text] [Related]
11. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
J Bone Miner Metab; 2009; 27(2):168-74. PubMed ID: 19183836
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Intern Med; 2008; 47(8):717-23. PubMed ID: 18421187
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
Majima T; Komatsu Y; Doi K; Takagi C; Shigemoto M; Fukao A; Morimoto T; Corners J; Nakao K
J Bone Miner Metab; 2006; 24(2):105-13. PubMed ID: 16502116
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
[TBL] [Abstract][Full Text] [Related]
15. Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
Iwasaki T; Takei K; Nakamura S; Hosoda N; Yokota Y; Ishii M
Pediatr Int; 2008 Jun; 50(3):269-75. PubMed ID: 18533934
[TBL] [Abstract][Full Text] [Related]
16. Comparison of concurrent treatment with vitamin K
Tanaka S; Miyazaki T; Uemura Y; Miyakawa N; Gorai I; Nakamura T; Fukunaga M; Ohashi Y; Ohta H; Mori S; Hagino H; Hosoi T; Sugimoto T; Itoi E; Orimo H; Shiraki M
J Bone Miner Metab; 2017 Jul; 35(4):385-395. PubMed ID: 27484436
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
18. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
19. Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial.
Mawatari T; Ikemura S; Matsui G; Iguchi T; Mitsuyasu H; Kawahara S; Maehara M; Muraoka R; Iwamoto Y; Nakashima Y
Bone Rep; 2020 Jun; 12():100275. PubMed ID: 32462056
[TBL] [Abstract][Full Text] [Related]
20. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
